AU2020272045B2 - Compounds, compositions and methods - Google Patents
Compounds, compositions and methodsInfo
- Publication number
- AU2020272045B2 AU2020272045B2 AU2020272045A AU2020272045A AU2020272045B2 AU 2020272045 B2 AU2020272045 B2 AU 2020272045B2 AU 2020272045 A AU2020272045 A AU 2020272045A AU 2020272045 A AU2020272045 A AU 2020272045A AU 2020272045 B2 AU2020272045 B2 AU 2020272045B2
- Authority
- AU
- Australia
- Prior art keywords
- disease
- pharmaceutically acceptable
- compound
- alkyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832775P | 2019-04-11 | 2019-04-11 | |
| US62/832,775 | 2019-04-11 | ||
| PCT/US2020/027742 WO2020210684A1 (en) | 2019-04-11 | 2020-04-10 | Compounds, compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020272045A1 AU2020272045A1 (en) | 2021-10-28 |
| AU2020272045B2 true AU2020272045B2 (en) | 2026-01-15 |
Family
ID=72752101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020272045A Active AU2020272045B2 (en) | 2019-04-11 | 2020-04-10 | Compounds, compositions and methods |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12358896B2 (https=) |
| EP (1) | EP3953348B1 (https=) |
| JP (1) | JP7623294B2 (https=) |
| KR (1) | KR20210151887A (https=) |
| CN (1) | CN113939294A (https=) |
| AR (1) | AR118641A1 (https=) |
| AU (1) | AU2020272045B2 (https=) |
| BR (1) | BR112021020027A2 (https=) |
| CA (1) | CA3136447A1 (https=) |
| DK (1) | DK3953348T3 (https=) |
| EA (1) | EA202192530A1 (https=) |
| ES (1) | ES3018383T3 (https=) |
| IL (1) | IL287120B2 (https=) |
| MA (1) | MA55624A (https=) |
| MX (1) | MX2021012392A (https=) |
| SG (1) | SG11202111058XA (https=) |
| TW (1) | TWI851710B (https=) |
| WO (1) | WO2020210684A1 (https=) |
| ZA (1) | ZA202107499B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
| EP4238975A4 (en) * | 2020-10-29 | 2024-06-12 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| CN116120291B (zh) * | 2023-04-11 | 2023-06-30 | 英矽智能科技(上海)有限公司 | 吲唑类化合物及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180208582A1 (en) * | 2016-06-16 | 2018-07-26 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2638031T3 (https=) | 2010-11-10 | 2018-03-10 | ||
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
-
2020
- 2020-04-08 AR ARP200101008A patent/AR118641A1/es unknown
- 2020-04-10 US US17/602,480 patent/US12358896B2/en active Active
- 2020-04-10 SG SG11202111058XA patent/SG11202111058XA/en unknown
- 2020-04-10 CN CN202080041217.0A patent/CN113939294A/zh active Pending
- 2020-04-10 IL IL287120A patent/IL287120B2/en unknown
- 2020-04-10 JP JP2021559818A patent/JP7623294B2/ja active Active
- 2020-04-10 TW TW109112173A patent/TWI851710B/zh active
- 2020-04-10 EP EP20787582.4A patent/EP3953348B1/en active Active
- 2020-04-10 ES ES20787582T patent/ES3018383T3/es active Active
- 2020-04-10 WO PCT/US2020/027742 patent/WO2020210684A1/en not_active Ceased
- 2020-04-10 CA CA3136447A patent/CA3136447A1/en active Pending
- 2020-04-10 DK DK20787582.4T patent/DK3953348T3/da active
- 2020-04-10 MX MX2021012392A patent/MX2021012392A/es unknown
- 2020-04-10 MA MA055624A patent/MA55624A/fr unknown
- 2020-04-10 BR BR112021020027A patent/BR112021020027A2/pt unknown
- 2020-04-10 KR KR1020217036412A patent/KR20210151887A/ko active Pending
- 2020-04-10 AU AU2020272045A patent/AU2020272045B2/en active Active
- 2020-04-10 EA EA202192530A patent/EA202192530A1/ru unknown
-
2021
- 2021-10-05 ZA ZA2021/07499A patent/ZA202107499B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180208582A1 (en) * | 2016-06-16 | 2018-07-26 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3953348A1 (en) | 2022-02-16 |
| CN113939294A (zh) | 2022-01-14 |
| TWI851710B (zh) | 2024-08-11 |
| EP3953348B1 (en) | 2024-12-18 |
| ZA202107499B (en) | 2022-06-29 |
| JP2022526015A (ja) | 2022-05-20 |
| ES3018383T3 (es) | 2025-05-16 |
| JP7623294B2 (ja) | 2025-01-28 |
| CA3136447A1 (en) | 2020-10-15 |
| SG11202111058XA (en) | 2021-11-29 |
| IL287120B1 (en) | 2025-02-01 |
| EP3953348A4 (en) | 2023-01-18 |
| TW202104213A (zh) | 2021-02-01 |
| EA202192530A1 (ru) | 2022-03-15 |
| AR118641A1 (es) | 2021-10-20 |
| WO2020210684A1 (en) | 2020-10-15 |
| KR20210151887A (ko) | 2021-12-14 |
| IL287120B2 (en) | 2025-06-01 |
| AU2020272045A1 (en) | 2021-10-28 |
| MX2021012392A (es) | 2021-11-12 |
| MA55624A (fr) | 2022-02-16 |
| US12358896B2 (en) | 2025-07-15 |
| US20220220094A1 (en) | 2022-07-14 |
| IL287120A (en) | 2021-12-01 |
| DK3953348T3 (da) | 2025-03-17 |
| BR112021020027A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11840529B2 (en) | Substituted pyrimidines as LRKK2 inhibitors | |
| EP3472153B1 (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| US20220153728A1 (en) | Compounds, compositions and methods | |
| WO2017096301A1 (en) | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) | |
| AU2020272045B2 (en) | Compounds, compositions and methods | |
| CN114805361B (zh) | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 | |
| HK40069073B (en) | Compounds, compositions and methods | |
| HK40069073A (en) | Compounds, compositions and methods | |
| EA050027B1 (ru) | Соединения, композиции и способы | |
| HK40074923A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| OA19864A (en) | Compounds, compositions, and methods. | |
| EA052777B1 (ru) | Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний | |
| HK40007576B (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| EA043797B1 (ru) | Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний |